Catechol-O-methyltransferase genotype is associated with plasma total homocysteine levels and may increase venous thrombosis risk

Summary

A disturbed methylation has been proposed as a mechanism via which homocysteine is associated with diseases like vascular disease, neural tube defects and mental disorders. Catechol- O-methyltransferase (COMT) is involved in the S-adenosylmethionine- dependent methylation of catecholamines and catecholestrogens and in this way contributes to homocysteine synthesis. COMT dysfunction has been related to schizophrenia and breast cancer. We hypothesized that COMT dysfunction by virtue of functional genetic polymorphisms may affect plasma total homocysteine (tHcy). Our primary objective was to study the association between common COMT polymorphisms and tHcy. Secondly, we evaluated these polymorphisms as a risk factor for recurrent venous thrombosis. We obtained genotype data from four polymorphisms in the COMT gene (rs2097603, rs4633, rs4680 [324G>A] and rs174699) from 401 populationbased controls. We performed haplotype analysis to investigate the association between common haplotypes and tHcy. In addition, we assessed the rs4680 variant as a genetic risk factor in a case-control study on recurrent venous thrombosis (n= 169). We identified a common haplotype that was significantly associated with tHcy levels. This effect was largely explained by the rs4680 variant, resulting in an increase in tHcy of 10.4% (95% CI 0.01 to 0.21, p=0.03) for 324AA compared with 324GG subjects. Interestingly, we found that the 324AA genotype was more common in venous thrombosis patients (OR 1.61 [95% CI 0.97 to 2.65], p=0.06) compared to control subjects. We show that the COMT rs4680 variant modulates tHcy, and might be associated with venous thrombosis risk as well.

Keywords

Homocysteine - haplotype - catechol-O-methyltransferase - venous thrombosis

^* These authors contributed equally to the manuscript.

• References

• 1 The Homocysteine Studies Collaboration.. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. J Am Med Assoc 2002; 288: 2015-2022.
• 2 Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. Br Med J 2002; 325: 1202.
• 3 den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a metaanalysis of published epidemiological studies. J Thromb Haemost 2005; 3: 292-299.
• 4 Clarke R, Smith AD, Jobst KA. et al. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol 1998; 55: 1449-1455.
• 5 Czeizel AE. Primary prevention of neural-tube defects and some other major congenital abnormalities: recommendations for the appropriate use of folic acid during pregnancy. Paediatr Drugs 2000; 2: 437-449.
• 6 Muntjewerff JW, Kahn RS, Blom HJ. et al. Homocysteine, methylenetetrahydrofolate reductase and risk of schizophrenia: a meta-analysis. Mol Psychiatry 2006; 11: 143-149.
• 7 Undas A, Brozek J, Ezczeklik A. Homocysteine and thrombosis: from basic science to clinical evidence. Thromb Haemost 2005; 94: 907-915.
• 8 James SJ, Melnyk S, Pogribna M. et al. Elevation in S-adenosylhomocysteine and DNA hypomethylation: potential epigenetic mechanism for homocysteine-related pathology. J Nutr 2002; 132 (Suppl. 08) 2361S-2366S.
• 9 Abdolmaleky HM, Cheng KH, Russo A. et al. Hypermethylation of the reelin (RELN) promoter in the brain of schizophrenic patients: a preliminary report. Am J Med Genet B Neuropsychiatr Genet 2005; 134: 60-66.
• 10 Bjorklund NK, Gordon R. A hypothesis linking low folate intake to neural tube defects due to failure of post-translation methylations of the cytoskeleton. Int J Dev Biol 2006; 50: 135-141.
• 11 Keijzer MB, den Heijer M, Borm GF. et al. Low fasting methionine concentration as a novel risk factor for recurrent venous thrombosis. Thromb Haemost 2006; 96: 492-497.
• 12 Yi P, Melnyk S, Pogribna M. et al. Increase in plasma homocysteine associated with parallel increases in plasma S-adenosylhomocysteine and lymphocyte DNA hypomethylation. J Biol Chem 2000; 275: 29318-29323.
• 13 Castro R, Rivera I, Struys EA. et al. Increased homocysteine and S-adenosylhomocysteine concentrations and DNA hypomethylation in vascular disease. Clin Chem 2003; 49: 1292-1296.
• 14 Mattson MP. Methylation and acetylation in nervous system development and neurodegenerative disorders. Ageing Res Rev 2003; 2: 329-342.
• 15 Brosnan JT, Jacobs RL, Stead LM. et al. Methylation demand: a key determinant of homocysteine metabolism. Acta Biochim Pol 2004; 51: 405-413.
• 16 Zhu BT. On the mechanism of homocysteine pathophysiology and pathogenesis: a unifying hypothesis. Histol Histopathol 2002; 17: 1283-1291.
• 17 Zhu BT. CNS dopamine oxidation and catechol- O-methyltransferase: importance in the etiology, pharmacotherapy, and dietary prevention of Parkinson’s disease. Int J Mol Med 2004; 13: 343-353.
• 18 Clarke Banfield. Chapter 7: S-adenosylmethionine- dependent methyltransferases. Homocysteine in health and disease. Cambridge University Press; 2001
• 19 Goodman JE, Lavigne JA, Wu K. et al. COMT genotype, micronutrients in the folate metabolic pathway and breast cancer risk. Carcinogenesis 2001; 22: 1661-1665.
• 20 Shifman S, Bronstein M, Sternfeld M. et al. A highly significant association between a COMT haplotype and schizophrenia. Am J Hum Genet 2002; 71: 1296-1302.
• 21 Zhu BT. Medical hypothesis: Hyperhomocysteinemia is a risk factor for estrogen-induced hormonal cancer. Int J Oncol 2003; 22: 499-508.
• 22 Chen J, Lipska BK, Halim N. et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet 2004; 75: 807-821.
• 23 Bray NJ, Buckland PR, Williams NM. et al. A haplotype implicated in schizophrenia susceptibility is associated with reduced COMT expression in human brain. Am J Hum Genet 2003; 73: 152-161.
• 24 den Heijer M, Blom HJ, Gerrits WB. et al. Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis?. Lancet 1995; 345: 882-885.
• 25 Muntjewerff JW, Gellekink H, den Heijer M. et al. Polymorphisms in catechol-O-methyltransferase and methylenetetrahydrofolate reductase in relation to the risk of schizophrenia. Eur Neuropsychopharmacol; 2007. epub ahead of print.
• 26 te Poele-Pothoff MT, van den Berg M, Franken DG. et al. Three different methods for the determination of total homocysteine in plasma. Ann Clin Biochem 1995; 32: 218-220.
• 27 Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
• 28 Lee SG, Joo Y, Kim B, Chung S. et al. Association of Ala72Ser polymorphism with COMT enzyme activity and the risk of schizophrenia in Koreans. Hum Genet 2005; 116: 319-328.
• 29 Barrett JC, Fry B, Maller J. et al. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265.
• 30 Handoko HY, Nyholt DR, Hayward NK. et al. Separate and interacting effects within the catechol- O-methyltransferase (COMT) are associated with schizophrenia. Mol Psychiatry 2005; 10: 589-597.
• 31 Lotta T, Vidgren J, Tilgmann C. et al. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 1995; 34: 4202-4210.
• 32 Geisel J, Hubner U, Bodis M. et al. The role of genetic factors in the development of hyperhomocysteinemia. Clin Chem Lab Med 2003; 41: 1427-1434.
• 33 Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999; 340: 1801-1811.
• 34 Lamberti P, Zoccolella S, Armenise E. et al. Hyperhomocysteinemia in L-dopa treated Parkinson’s disease patients: effect of cobalamin and folate administration. Eur J Neurol 2005; 12: 365-368.
• 35 Lamberti P, Zoccolella S, Iliceto G. et al. Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson’s disease patients. Mov Disord 2005; 20: 69-72.
• 36 Yasui K, Nakaso K, Kowa H. et al. Levodopa-induced hyperhomocysteinaemia in Parkinson’s disease. Acta Neurol Scand 2003; 108: 66-67.
• 37 Souto JC, Blanco-Vaca F, Soria JM. et al. A genomewide exploration suggests a new candidate gene at chromosome 11q23 as the major determinant of plasma homocysteine levels: results from the GAIT project. Am J Hum Genet 2005; 76: 925-933.